Φ
Read This First
Philosophy & Blood Pressure Targets
Hypertension is the most modifiable cardiovascular risk factor we manage. Uncontrolled HTN drives LVH, diastolic dysfunction, AFib, heart failure, stroke, and CKD — often silently, over years. Our approach is proactive and stepwise, with clear medication preferences and a short list of agents we never use.
Blood Pressure Targets by Clinical Context
| Clinical Context | Target BP | Notes |
|---|---|---|
| General population | < 130/80 mmHg | Standard target for most patients in this practice |
| Diabetes | < 130/80 mmHg | ARB preferred — renal-protective |
| CKD (±proteinuria) | < 130/80 mmHg | ARB or ACEi preferred; monitor K⁺ and creatinine closely |
| Post-stroke / high stroke risk | < 130/80 mmHg | Aggressive control reduces recurrence risk |
| HFrEF | < 130/80 mmHg | ARB + beta-blocker synergy; avoid CCBs (diltiazem/verapamil) |
| Very elderly / frail (individualize) | < 140/90 mmHg acceptable | Balance CV benefit against fall/orthostasis risk |
Bottom Line
For the overwhelming majority of patients in this practice, the target is <130/80 mmHg. If you're uncertain — aim lower.
WC
Common Deflection — Address Directly
"White Coat Hypertension"
White coat hypertension is real, but it is vastly over-invoked by patients who prefer not to treat. The correct response is not to dismiss the reading — it is to objectively characterize the patient's BP pattern outside the clinic. Don't debate it. Offer objective measurement.
Remote Blood Pressure Monitoring (RBPM)
The Right Answer to "White Coat" Concerns
RBPM provides objective, multi-day BP data collected outside the clinic — completely eliminating the white coat argument with actual evidence.
Covered under Medicare + G supplement — identify appropriate patients and offer it proactively. Provides 24-hour ambulatory-like BP characterization across multiple time points and activity levels.
We are also in the process of developing a formal Ambulatory Blood Pressure (ABP) monitoring program — not yet launched, but coming soon. Watch for updates.
Medicare + G Supplement Covered
Covered under Medicare + G supplement — identify appropriate patients and offer it proactively. Provides 24-hour ambulatory-like BP characterization across multiple time points and activity levels.
We are also in the process of developing a formal Ambulatory Blood Pressure (ABP) monitoring program — not yet launched, but coming soon. Watch for updates.
1
Step 1
Confirm the Diagnosis
BP Measurement Technique Matters
Patient seated · feet flat · arm at heart level · no talking · Two readings 1–2 minutes apart, average both · Confirm in both arms at initial visit; use the higher arm going forward · Discrepancy >15 mmHg arm-to-arm → consider subclavian stenosis or aortic disease
BP Classification (ACC/AHA)
| Category | Systolic | Diastolic | Action |
|---|---|---|---|
| Normal | < 120 | and < 80 | Lifestyle counseling; recheck annually |
| Elevated | 120–129 | and < 80 | Lifestyle modification; recheck in 3–6 months |
| Stage 1 HTN | 130–139 | or 80–89 | Lifestyle ± medication based on 10-yr CVD risk |
| Stage 2 HTN | ≥ 140 | or ≥ 90 | Lifestyle + initiate medication |
| Hypertensive Urgency | ≥ 180 | and/or ≥ 120 | No end-organ damage; oral therapy; recheck 24–48 hrs |
| Hypertensive Emergency | ≥ 180 | and/or ≥ 120 | End-organ damage present — immediate ER transfer (see Step 8) |
2
Step 2
Initial Workup
Order at Baseline — All New HTN Diagnoses
| Test | Purpose |
|---|---|
| BMP / CMP | Creatinine, eGFR, K⁺ (baseline before RAAS agents), Na⁺ (before diuretics), glucose |
| Fasting lipid panel | CV risk stratification |
| HbA1c | Diabetes screening and risk stratification |
| TSH | Hypothyroidism as secondary cause of HTN |
| Urinalysis + urine protein/creatinine | CKD screening; secondary HTN evaluation |
| CBC | Baseline; polycythemia can drive hypertension |
| EKG | LVH pattern, arrhythmia, baseline rhythm |
| Echocardiogram | See Step 3 — essential in most patients with new HTN |
Secondary causes to actively rule out — especially in resistant HTN:
- Obstructive Sleep Apnea — extremely low threshold for screening; see Step 3
- Primary hyperaldosteronism — aldosterone/renin ratio if K⁺ low or HTN resistant
- Renal artery stenosis — especially HTN onset before age 30 or after 55, or resistant HTN
- Pheochromocytoma — paroxysmal HTN, headache, diaphoresis, palpitations → 24-hr urine catecholamines
- Hypothyroidism / hyperthyroidism — TSH (already ordered above)
- Cushing's syndrome — if habitus suggests → 24-hr urine cortisol
- Coarctation of the aorta — BP differential arms vs. legs; consider in younger patients
3
Step 3 — Do Not Skip
Echo & OSA Screening
Order an echo in: all new HTN patients with any cardiac symptoms · EKG evidence of LVH · resistant HTN · suspected diastolic dysfunction · any patient being considered for Entresto.
LV Hypertrophy (LVH)
Chronic Pressure Overload
BP has been poorly controlled over time. Drives diastolic dysfunction and significantly elevates AFib risk. A key finding that escalates treatment urgency.
Concentric Remodeling
Early Hypertensive Response
Increased relative wall thickness with normal LV mass. Precedes frank LVH. An early warning sign — do not wait for it to progress.
LA Enlargement
Chronically Elevated Filling Pressures
Marker of diastolic dysfunction. Independently predicts AFib risk. Often the first structural sign of hypertensive heart disease on echo.
Diastolic Dysfunction (Grade I–III)
Impaired LV Relaxation
Result of hypertensive remodeling. May be symptomatic (exertional dyspnea, orthopnea). Opens the door for Entresto consideration — see Step 9.
These Findings Are Not Incidental
LVH, concentric remodeling, and LA enlargement tell you the patient's hypertension has been causing real, structural consequences — regardless of what they report about symptoms. Use these findings to motivate treatment urgency with the patient directly.
OSA Screening — Extremely Low Threshold
Obstructive Sleep Apnea & Resistant HTN
OSA is one of the most common, most underdiagnosed, and most reversible causes of secondary hypertension. Untreated OSA drives nocturnal BP surges, sympathetic activation, and structural cardiac remodeling that directly counteracts antihypertensive therapy.
Screen for OSA in: Resistant HTN (≥2 meds not at goal) · LVH, LA enlargement, or diastolic dysfunction on echo · BMI >30 · Nocturnal symptoms (snoring, witnessed apneas, morning headache, nocturia, excessive daytime sleepiness) · Male patients with HTN and neck circumference >17 inches
Do not wait for multiple medication failures. OSA treatment changes everything.
Screen for OSA in: Resistant HTN (≥2 meds not at goal) · LVH, LA enlargement, or diastolic dysfunction on echo · BMI >30 · Nocturnal symptoms (snoring, witnessed apneas, morning headache, nocturia, excessive daytime sleepiness) · Male patients with HTN and neck circumference >17 inches
Do not wait for multiple medication failures. OSA treatment changes everything.
Referral: Refer to Dr. Andrew Hsing or another sleep specialist for formal sleep study evaluation as soon as OSA is suspected.
4
Step 4 — Always First, Always Ongoing
Lifestyle Modifications
Lifestyle Interventions & Expected SBP Impact
| Intervention | Expected SBP Reduction | Key Guidance |
|---|---|---|
| Weight loss | ~1 mmHg per kg lost | Most impactful single intervention; 10 kg loss → ~10 mmHg reduction |
| Low-sodium diet | 4–5 mmHg | Target <1,500 mg/day; most Americans consume >3,500 mg/day; label reading is key |
| DASH diet | 8–14 mmHg | Emphasizes K⁺, Ca²⁺, Mg²⁺; particularly effective for systolic HTN |
| Aerobic exercise | 4–9 mmHg | 30 min, 5 days/week moderate intensity |
| Alcohol reduction | 2–4 mmHg | <2 drinks/day men; <1 drink/day women |
| Smoking cessation | Indirect benefit | Acute nicotine raises BP; cessation lowers overall CV risk |
| Stress reduction / sleep hygiene | Variable | Chronic stress and poor sleep drive catecholamine-mediated HTN |
Timing Rule
Stage 1 HTN, low CVD risk: 3-month lifestyle trial before initiating medication.Stage 2 HTN or any established ASCVD: Start medication now alongside lifestyle — do not delay.
5
Step 5 — Stepwise Approach
Medication Selection
At-a-Glance: Dr. Rasch's Antihypertensive Ladder
| Line | Agent(s) | Notes |
|---|---|---|
| 1st Line | Valsartan | Preferred in most patients; ARB — no cough |
| 2nd Line | Amlodipine | Max 5 mg QD or 5 mg BID in this practice |
| 3rd Line | Spironolactone (women) · Eplerenone (men) | Resistant HTN; close K⁺ monitoring required |
| 4th Line | HCTZ 12.5 mg → Chlorthalidone | Watch Na⁺; avoid if Na⁺ ~135 mEq/L or lower |
| 5th Line | Nebivolol → Carvedilol → Labetalol | Not first-line for uncomplicated HTN; Metoprolol is a poor antihypertensive |
| 6th Line | Hydralazine | Short-acting; last resort only; no end-organ protection |
| 7th Line | Doxazosin (Cardura) | Extreme last resort; orthostasis risk; never monotherapy |
| ⛔ NEVER | Clonidine | Never used in this practice — under any circumstances |
Valsartan (Diovan)
Angiotensin II Receptor Blocker (ARB)
ValsartanDiovan / generic
Start: 40–80 mg QD · Titrate to: 160 mg QD · Max: 320 mg QD
Check K⁺ and creatinine 1–2 weeks after initiation and each dose increase
ARBs are better tolerated than ACE inhibitors — no cough, lower angioedema risk. Renal-protective in diabetic nephropathy and CKD with proteinuria. Do not combine with an ACE inhibitor — dual RAAS blockade increases hyperkalemia, hypotension, and AKI risk.
A creatinine rise up to 30% after initiation is acceptable and expected (reduced glomerular hyperfiltration). Rise >30% or K⁺ >5.5 — hold and reassess.
Contraindications: Pregnancy (absolute) · Bilateral renal artery stenosis · K⁺ >5.5 at baseline · Prior angioedema with any RAAS agent
A creatinine rise up to 30% after initiation is acceptable and expected (reduced glomerular hyperfiltration). Rise >30% or K⁺ >5.5 — hold and reassess.
Contraindications: Pregnancy (absolute) · Bilateral renal artery stenosis · K⁺ >5.5 at baseline · Prior angioedema with any RAAS agent
Amlodipine (Norvasc)
Calcium Channel Blocker (Dihydropyridine CCB)
AmlodipineNorvasc / generic
Start: 2.5–5 mg QD
Preferred max in this practice: 5 mg QD or 5 mg BID BID dosing may reduce peak-trough BP variability and peripheral edema compared to 10 mg QD
Preferred max in this practice: 5 mg QD or 5 mg BID BID dosing may reduce peak-trough BP variability and peripheral edema compared to 10 mg QD
Excellent for isolated systolic hypertension. No metabolic effects. Most common side effect: peripheral edema (dose-dependent — splitting to BID often helps).
If a patient transfers in on 10 mg QD and is tolerating it — continue. But Dr. Rasch does not typically initiate at 10 mg QD.
If a patient transfers in on 10 mg QD and is tolerating it — continue. But Dr. Rasch does not typically initiate at 10 mg QD.
Aldosterone Antagonists
Mineralocorticoid Receptor Antagonists — Resistant HTN
⚠ Close K⁺ Monitoring Required
Check K⁺ and creatinine at baseline, 1–2 weeks post-initiation, and after each dose change. Do not start if K⁺ >5.0. Hold if K⁺ >5.5. Avoid or use with extreme caution in CKD stage 3b+ (eGFR <45).
SpironolactoneAldactone — Preferred in Women
12.5–50 mg QD · Start low; titrate slowly
Women often appreciate scalp hair thickening — mention this proactively, it improves adherence. Anti-androgenic effects may cause gynecomastia and sexual side effects in men — prefer eplerenone in men.
EplerenoneInspra — Preferred in Men
25–50 mg QD or BID
Selective mineralocorticoid antagonist — no anti-androgenic effects. No gynecomastia or sexual side effects. Slightly less potent than spironolactone mg-for-mg. May require prior auth.
Thiazide Diuretics
Fourth-Line — Monitor Electrolytes Closely
HCTZHydrochlorothiazide — Standard
12.5 mg QD (typical starting dose in this practice) · Maximum 25 mg QD
Monitor Na⁺, K⁺, glucose, creatinine
ChlorthalidoneLonger-acting — Resistant HTN
12.5–25 mg QD
More potent and longer-acting than HCTZ. Preferred when a thiazide is needed for resistant HTN. Higher hyponatremia risk due to long half-life — monitor Na⁺ closely.
⚠ Na⁺ Caution — Important
Do not initiate any thiazide if baseline Na⁺ is on the low end of normal (~135 mEq/L or below) — thiazides will drive it lower and risk symptomatic hyponatremia, particularly in elderly patients. Check Na⁺ 1–2 weeks after initiation.
Beta-Blockers
Not first-line for uncomplicated HTN — preference order matters
NebivololBystolic — Preferred
5–40 mg QD
Highly selective β₁ blocker + NO-mediated vasodilation. Very well tolerated. Minimal metabolic effects. Least fatigue of the beta-blockers.
CarvedilolCoreg — 2nd Choice
3.125–25 mg BID
Non-selective β + α₁ blocker; additional vasodilatory benefit. Preferred if concurrent HFrEF.
LabetalolTrandate — 3rd Choice
100–400 mg BID
Non-selective β + α₁ blocker. Useful in pregnancy-related HTN.
MetoprololLopressor / Toprol — Avoid for HTN
Generally a poor antihypertensive in this practice. Less vasodilatory, more metabolically adverse, and clinically less effective for BP lowering than nebivolol or carvedilol. If a patient is already on metoprolol for HF or rate control — continue it. Do not start it specifically for HTN management.
⛔ Never Use — Under Any Circumstances
Clonidine
Clonidine is a centrally-acting alpha-2 agonist with a short duration of action, significant CNS side effects (sedation, cognitive blunting, depression), and a dangerously rebound-prone discontinuation profile. Abrupt discontinuation can precipitate hypertensive crisis. There is no clinical scenario in which Dr. Rasch uses or endorses clonidine for hypertension management. This is a hard rule with no exceptions.
Hydralazine
Direct Vasodilator — Last-Line Only
Hydralazine
10–75 mg BID–TID
Short-acting — requires multiple daily doses. No end-organ protection, no mortality benefit. Side effects: reflex tachycardia, fluid retention, lupus-like syndrome with long-term use. Use only when truly out of other options.
Doxazosin (Cardura)
Alpha-1 Blocker — Extreme Last Resort
DoxazosinCardura
1–16 mg QD
Significant orthostatic hypotension risk — especially in elderly. May have utility in men with concurrent BPH. Never as monotherapy. ALLHAT trial: increased HF events vs. chlorthalidone. Exhaust all other options first.
6
Step 6
Resistant Hypertension
Resistant HTN = BP not at goal despite 3 adequate antihypertensive medications at appropriate doses, including a diuretic.
Before Labeling as Resistant — Confirm All of These
☐ Medication adherence confirmed — ask directly, non-judgmentally☐ Proper BP measurement technique verified
☐ White coat effect ruled out — offer RBPM
☐ BP-raising medications reviewed and removed if possible: NSAIDs · decongestants · stimulants · OCPs · steroids · SNRIs · energy drinks
☐ Secondary HTN ruled out (renal artery stenosis, pheochromocytoma, hyperaldosteronism)
☐ OSA screened — if not already done, do it now
Escalation Sequence for Resistant HTN
| Step | Action |
|---|---|
| 1 | Ensure valsartan + amlodipine + HCTZ are all at optimal doses before adding anything new |
| 2 | Switch HCTZ to chlorthalidone — longer-acting, more effective for resistant HTN |
| 3 | Add aldosterone antagonist: eplerenone (men) or spironolactone (women) — often transformative in truly resistant HTN; monitor K⁺ closely |
| 4 | Add beta-blocker: nebivolol preferred |
| 5 | Consider Entresto off-label — especially if echo shows diastolic dysfunction, LVH, or LA enlargement (see Step 9) |
| 6 | Escalate to Dr. Rasch — resistant HTN workup and advanced management discussion |
7
Step 7
Monitoring & Follow-Up
1–2 Weeks Post-Initiation
K⁺ and Creatinine Recheck
Essential after any ARB, ACEi, or aldosterone antagonist initiation or dose change. Also check Na⁺ 1–2 weeks after any diuretic initiation or dose change.
4–6 Weeks
BP Recheck & Tolerability
Assess BP response. Review side effects. Uptitrate if not at goal — do not wait multiple months at a subtherapeutic dose.
3 Months
Full BP Reassessment
Full BP review. Labs if on diuretic or RAAS agent (K⁺, Na⁺, creatinine). Lifestyle review — weight, sodium intake, OSA follow-up if applicable.
Every 6 Months (Stable)
Maintenance Check
BP, K⁺, creatinine, sodium (if on diuretic). Review for new medications that may raise BP. Reinforce adherence and lifestyle.
Annually
Full Metabolic Panel + EKG
CMP, lipids, HbA1c, EKG. Reassess CV risk. Consider repeat echo if LVH or diastolic dysfunction was previously identified — assess for regression with treatment.
Patient Education — Every Visit
Home BP monitoring strongly encouraged — morning and evening, average 3 readings over 1 week · Low-sodium diet: label reading, restaurant awareness · Never stop BP medications abruptly (especially beta-blockers — rebound tachycardia) · Weight loss: even 5–10 lbs has meaningful BP benefit
8
Step 8
Hypertensive Urgency & Emergency
Urgency vs. Emergency — Know the Difference
| Scenario | Definition | Management |
|---|---|---|
| Urgency | SBP ≥180 / DBP ≥120 · No end-organ damage | Oral therapy in clinic; restart/intensify antihypertensives; recheck 24–48 hrs; send to ER if unable to manage outpatient |
| Emergency | SBP ≥180 / DBP ≥120 · With end-organ damage | Immediate ER transfer — do not manage outpatient. Follow ER transfer protocol below. |
🚨 ER Transfer Protocol — Hypertensive Emergency
- Ask front-desk staff to request hospital transfer via campus security (golf cart). EMS only if patient is critical.
- Call Scripps ER triage officer at 760-633-7686 and notify of pending transfer and clinical status.
- Complete and sign the clinic note immediately so it is available for ED staff on arrival.
Signs of End-Organ Damage — Recognize These
| Organ System | Signs / Symptoms | Syndrome |
|---|---|---|
| Cardiac | Chest pain, ST changes, troponin elevation | Hypertensive ACS |
| Pulmonary | Acute dyspnea, pulmonary edema, orthopnea | Hypertensive acute HF |
| Neurologic | Focal deficits, altered mentation, seizure | Hypertensive encephalopathy / stroke |
| Ophthalmologic | Visual changes, papilledema | Hypertensive retinopathy / PRES |
| Renal | Rapid creatinine rise, hematuria | Hypertensive nephropathy |
9
Step 9 — Off-Label · Discuss with Dr. Rasch First
Entresto for Resistant HTN / Diastolic Dysfunction
⚠ Off-Label Use — Discuss With Dr. Rasch Before Initiating
Entresto (sacubitril/valsartan) is not FDA-indicated for hypertension. Dr. Rasch uses it off-label in select patients. This is an advanced decision — do not initiate without discussing with Dr. Rasch first. When used appropriately, it works extremely well.
Entresto (Sacubitril / Valsartan)
Off-Label · Resistant HTN / Diastolic Dysfunction
When to Consider
Resistant HTN not at goal despite multiple optimized agents · Echo evidence of diastolic dysfunction (Grade I–III) · LVH, concentric remodeling, or significant LA enlargement · Symptomatic HFpEF with elevated BPs
Why It Works
The neprilysin inhibitor component (sacubitril) reduces natriuretic peptide degradation → promotes natriuresis, vasodilation, and cardiac unloading. The valsartan component provides standard ARB mechanism. Net effect: potent BP lowering + favorable reverse remodeling of the hypertensive heart.
Dosing
24/26 mg BID (starting) → 49/51 mg BID → target 97/103 mg BID as tolerated
Critical Rules
Never combine with ACE inhibitors — 36-hour washout required when switching from any ACEi.
Never combine with standalone valsartan — do not double the ARB component.
Monitor K⁺, creatinine, and BP closely after initiation.
Never combine with standalone valsartan — do not double the ARB component.
Monitor K⁺, creatinine, and BP closely after initiation.
Insurance
Will usually require documentation of HFpEF or HFrEF for approval. Dr. Rasch will guide documentation strategy for prior auth.
10
Step 10
Escalate to Dr. Rasch If…
When in doubt — always better to ask.
Hypertensive emergency — activate ER transfer protocol simultaneously
BP not at goal on ≥3 optimized medications — resistant HTN workup and escalation discussion
Considering Entresto — discuss every case without exception before initiating
Echo evidence of significant LVH, diastolic dysfunction, or reduced EF found
Suspected secondary HTN — renal artery stenosis, pheochromocytoma, primary hyperaldosteronism
K⁺ >5.5 or creatinine rise >30% after RAAS agent initiation
Severe symptomatic hyponatremia after diuretic initiation
OSA confirmed — loop Dr. Rasch in on how OSA treatment should change the antihypertensive strategy
Any scenario where you are uncertain — always better to ask than to proceed alone.